- freely available
Cancers 2014, 6(1), 193-210; doi:10.3390/cancers6010193
Published: 27 January 2014
Abstract: The transcription factors and proto-oncogenes STAT3 and STAT5 are highly activated in hematological malignancies and represent promising therapeutic targets. Whereas the importance of STAT5 as tumor promoter is beyond doubt, the role of STAT3 in hematological cancers is less well understood. Both, enforced as well as attenuated expression of STAT3 were reported in hematopoietic malignancies. Recent evidence implicates STAT3 as key player for tumor immune surveillance as it both mediates the production of and response to inflammatory cytokines. Here we investigated the effects of STAT3 deletion in a BCR/ABL-induced lymphoma model, which is tightly controlled by natural killer (NK) cells in vivo. Upon STAT3 deletion tumor growth is significantly enhanced when compared to STAT3-expressing controls. The increased tumor size upon loss of STAT3 was accompanied by reduced NK cell infiltration and decreased levels of the cytokine IFN-γ and the chemokine RANTES. Upon transplantation into NK cell-deficient mice differences in lymphoma size were abolished indicating that STAT3 expression in the tumor cells controls NK cell-dependent tumor surveillance. Our findings indicate that STAT3 inhibition in lymphoma patients will impair NK cell-mediated tumor surveillance, which needs to be taken into account when testing STAT3 inhibitors in preclinical or clinical trials.
Tumorigenesis involves both tumor-intrinsic alterations as well as modulations of the tumor environment finally favoring tumor growth and maintenance. Transformation of a cell requires the expression of oncogenes or silencing of tumor suppressor genes . Most malignancies remain dependent on the transforming oncogene, a process that is described as “oncogene addiction” and well described for oncoproteins such as BCR/ABL or EGFR . Tumor cells may also acquire additional adaptations or changes in signaling pathways that they may become dependent on—a phenomenon called “non-oncogene addiction” . Luo et al. hypothesized that interference with such signaling pathways would result in system failure and tumor cell death. Players of the JAK/STAT pathway—in particular STAT3 and STAT5—have been repeatedly shown to represent such critical factors [4,5,6,7,8].
STAT3 was shown to be persistently activated in a variety of solid and hematological cancers [5,6,9,10] and to promote metastasis [11,12,13]. Constitutive STAT3 activation relieves tumor cells from their dependence on cytokines and growth factors—thereby allowing continuous cell cycle progression and proliferation. Recently STAT3 was shown to support transformation via a metabolic function in mitochondria [14,15]. Concordantly, constitutively active STAT3 (STAT3αC)-expressing mice showed accelerated skin tumor formation upon UVB irradiation . Moreover, crossing of MMTV-neu transgenic mice to STAT3αC-knock-in animals resulted in an earlier onset of mammary tumor formation accompanied by increased invasiveness . Constitutive activation of the JAK/STAT pathway was described in patient-derived BCR/ABL+ leukemic cells [17,18,19,20]. The tumor promoting role of STAT3 in leukemia formation has been confirmed in mice: transduction of bone marrow (BM) with constitutively active versions of STAT3 rapidly induced leukemia in mice . Tumor formation occurred spontaneously and in the absence of a driving oncogene: STAT3αC alone sufficed to induce leukemia. These observations prompted current investigations evaluating STAT3 as a prognostic biomarker in patients suffering from acute forms of leukemia (NCT01245231, NCT01138332, and NCT01057290). STAT3 inhibitors and antisense oligonucleotides are presently undergoing biosafety studies in clinical trials (NCT00955812, NCT00696176, NCT01563302, NCT01904123, NCT01423903, NCT01867073 and NCT01066663).
However, the role of STAT3 for tumor formation appears complex. A variety of studies described STAT3 as a tumor suppressor [21,22,23,24]. Ecker et al. observed a proliferative disadvantage of fibroblasts and suppression of myc-induced foci formation in the presence of STAT3αC . In line, the subcutaneous injection of myc+STAT3αC+ fibroblasts resulted in a profound reduction of tumor weight. Moreover, Mair et al. described that conditional inactivation of STAT3 in hepatocytes and cholangiocytes aggravated bile acid-induced liver injury and fibrosis  thereby implicating a protective role of STAT3.
Tumor development is shaped and sculptured by external influences such as the surrounding immune system . Immune cells continuously screen our body to detect and eradicate degenerated or transformed cells. Tumor surveillance is dominated by the interplay of myeloid cells, cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. NK cells are the main players for the eradication of leukemic cells transformed by the BCR/ABL oncogene [27,28,29]. NK-dependent surveillance requires their recruitment, recognition and subsequent lysis of target cells. Attraction of NK cells is mediated by chemokines, such as CCL5 (or RANTES, binding CCR5), CCL19 and CCL21 (binding CCR7), CXCL10 (binding CXCR3) and CXCL12 (binding CXCR4) that are secreted by other immune cells or the tumor itself . Recognition of tumor cells by NK cells is triggered by low MHC class I levels (“missing-self”) or enhanced expression of stress signals such as NKG2D ligands [31,32]. Receptor-receptor interactions between NK and target cells induce cytotoxicity that is either delivered through exocytosis of granules packed with lytic enzymes (e.g., perforin and granzymes) or by producing cytokines such as interferon (IFN)-γ stimulating adaptive immune responses.
STAT3 has many facets in cancer and may act as tumor promoter and tumor suppressor. STAT3 induces target gene transcription of pro-survival and proliferative genes such as Bcl2 or cyclin D1 that promote tumor growth and survival. Another layer of complexity comes from the fact that STAT3 is critically involved in the production of immune-modulatory cytokines such as IL-6, IL-10, IL-17 and IFN-γ [33,34] and pro-angiogenic factors like VEGF . Persistent STAT3 activity may provoke synthesis of IL-10, IL-17 and VEGF. Moreover, STAT3 represents a critical player downstream of these cytokines. In summary, STAT3 is part of a feed-forward loop that results in immunosuppression and inflammation . The inhibition or genetic ablation of STAT3 relieves immunosuppression and thus markedly ameliorates anti-tumor responses [36,37].
Given the delicate balance between STAT3’s tumor promoting and tumor suppressing actions it is critical to assess the net effect of STAT3 inhibition within the tumor and the impact on tumor surveillance. In this study we used a conditional Stat3 knockout mouse model to investigate the consequences of Stat3 deletion for BCR/ABLp185+-driven tumor growth. Intriguingly, we found that STAT3-deficient tumors were substantially larger, which was accompanied by reduced NK cell recruitment to the tumor. NK cell cytotoxicity is significantly lower against STAT3-deficient compared to STAT3-expressing tumor cells. In line with this, pro-inflammatory cytokines such as IL-6, IFN-γ, TNF-α and RANTES are markedly reduced in STAT3-deficient tumors.
2. Results and Discussion
2.1. Generation of STAT3-Deficient BCR/ABL+ Pro-B Cell Lines
Single cell suspensions of BM derived from Stat3fl/fl Mx1-Cre and wild-type mice were infected retrovirally with the BCR/ABLp185 oncogene. After three weeks, stable growth-factor-independent BCR/ABLp185+ cell lines were established. Two independent approaches to delete STAT3 in these BCR/ABLp185+ cells were used. First, we deleted the endogenous Stat3 locus in BCR/ABLp185+ Stat3fl/flMx1-Cre cell lines by IFN-β treatment (further on named Stat3∆/∆). Ten days thereafter loss of STAT3 was confirmed by western blotting. We also tested whether any other closely related STAT family members would compensate for the absence of STAT3. As depicted in Figure 1A protein levels of STAT1 and STAT5 were unaltered upon STAT3 deletion. In an additional approach STAT3 was reduced using lentiviral knockdown in two independently derived wild-type pro-B cell lines (#1 being transformed by v-ABLp160, #4 by BCR/ABLp185). This resulted in a STAT3 knockdown of 64% and 48% compared to control cells, respectively (Figure 1B). FACS analysis verified that the expression of B cell-specific markers (CD19 and B220) was unaltered upon loss of STAT3 (Figure 1C).
2.2. In Vitro Proliferation of BCR/ABL+ Cells Expressing or Lacking STAT3
STAT3 is an important mediator of cell growth and survival [33,38,39]. Thus, inhibition of STAT3 in tumor patients has been proposed as a promising therapeutic strategy . Together with STAT3, STAT5 was repeatedly described to be constitutively activated and to mediate tumor cell survival and proliferation [41,42,43,44]. As STAT3 and STAT5 share common anti-apoptotic and cell cycle-regulating target genes, it was speculated that they share redundant functions. However, in BCR/ABL-transformed cells survival depends on STAT5 but not on STAT3: deletion of Stat5 resulted in a cell cycle arrest in G1 followed by apoptosis . Apoptosis was not induced by deletion of Stat3 . We found that Stat3fl/fl and Stat3∆/∆ cell lines showed superimposable proliferation rates (Figure 2A). Further, we could not detect any differences in proliferation between cell lines harboring a STAT3 KD or a control hairpin (Figure 2B). Accordingly, cell cycle profiles of STAT3-expressing and STAT3-deficient cells under normal culturing conditions were unaltered (Figure 2C,D).
2.3. Lymphoma Development in Vivo
In vitro proliferation of transformed cell lines only partially reflects in vivo tumor formation. Within an organism tumor cells are exposed to a variety of cytokines that may affect survival and proliferation. Importantly the majority of these cytokines signals via the JAK/STAT cascade. STAT3 mediates target gene expression downstream of pro-inflammatory cytokines such as IL-6, TNF-α or IL-10 . We thus speculated that despite the unaltered tumor cell proliferation in vitro, there may be a difference in tumor growth in vivo. To test this, Stat3fl/fl and Stat3∆/∆ BCR/ABLp185+ cells were injected subcutaneously into the flanks of C57BL/6 wild-type mice. Intriguingly, after 11 days STAT3-deficient lymphoma sizes were significantly increased compared to wild-type tumors. The increased tumor size was evident irrespective whether the STAT3 abrogation was achieved genetically (Figure 3A) or by lentiviral knockdown (Figure 3B).
Staining of tumor sections with H&E, Ki67 and CD31 revealed obvious differences. Whereas we failed to detect any alterations in the degree of necrosis (Figure 3C), Stat3∆/∆ tumor boundaries were less definite and the infiltrative character was more pronounced compared to Stat3fl/fl controls (Figure 3D). The invasive front of Stat3∆/∆ tumors was demarcated by formation of granulation tissue (Figure 3D, see arrows), which was also evident from the increased formation of nascent blood vessels at the marginal tumor area (Figure 3E). In contrast, STAT3-expressing tumors hardly harbored granulation tissue (Figure 3D,E). Within the tumor lymph and blood vessel densities were unaltered (data not shown). Ki67 staining unraveled a substantially enhanced proliferation of STAT3-deficient tumor cells in vivo (Figure 3F), which stands in clear contrast to our observations in vitro.
Taken together, deletion of STAT3 in BCR/ABL+ lymphoma resulted in an aggravation of tumor burden. At a first glance these results may be difficult to reconcile as they oppose studies by others, who defined STAT3 as a proto-oncogene [46,47]. Indeed there is growing evidence that STAT3 acts as a tumor suppressor in certain tissues [21,22,23,24]. Depending on the cellular system and on the oncogene that drives transformation STAT3 may thus be either considered a tumor suppressor or a tumor promoter. In the case of BCR/ABL+ lymphoma STAT3 acts as a tumor suppressor.
2.4. Cytokine Profile in STAT3-Deficient Lymphomas
The discrepancies between our in vitro and in vivo findings might result from the cytokine milieu that influences tumor growth in vivo. The involvement of STAT3 in cytokine signaling and production may contribute to the altered granulation tissue and blood vessel formation as well as cell proliferation in STAT3-deficient tumors.
We thus compared the expression levels of a number of candidate cytokines of in vitro growing and ex vivo derived tumor cells by real-time PCR concentrating on cytokines that either depend on STAT3 for production or signaling. The expression levels of IL-10, CXCL1, CXCL2, CCL2, CCL7 and VEGF were unaltered (Figure 4 and data not shown). In contrast, Stat3∆/∆ tumor tissue expressed reduced mRNA levels of IL-6 (607 vs. 256, p = 0.09), IL-17 (15.6 vs. 8.3, p = 0.09), IFN-γ (63 vs. 20, p = 0.012) and TNF-α (5.3 vs. 1.3, p = 0.031) (Figure 4). Previous reports have implicated the involvement of IFN-γ and TNF-α in proliferation and wound healing. Upon injury, IFN-γ-  as well as TNF-α-deficient animals  develop augmented granulation tissue and vessel formation. Accordingly, the reduced levels of IFN-γ and TNF-α in STAT3-deficient lymphomas are likely to contribute to the occurrence of granulation tissue and enhanced proliferation in these tumors.
Further, we found significantly lower expression of CCL5 (RANTES) in STAT3-deficient tumor cell lines in vitro as well as in STAT3-deficient lymphoma samples ex vivo (Figure 4). The chemokine CCL5 recruits and stimulates leukocytes to elicit anti-tumor immunity [50,51,52]. Further, CCL5 was described as a downstream target of TNF-α, which itself acts as a chemo-attractant for myeloid cells . These findings prompted us to investigate the composition and amount of lymphoma-infiltrating leukocytes.
2.5. Lymphoma-Infiltrating Leukocytes
The majority of the cytokines we tested is produced rather by the tumor microenvironment than by the tumor cells themselves (Figure 4). This suggested that different numbers or an altered composition of lymphoma-infiltrating leukocytes may be present. As depicted in Figure 5A we indeed detected slight changes in the recruitment of CD4+ and CD8+ T cells in STAT3-deficient tumors that however did not meet the criterion of being statistically significant. Numbers of GR1+CD11b+ myeloid cells were comparable. Intriguingly, we found a statistically significant reduction in NK cells in STAT3-deficient tumors (1.1% ± 0.26% in Stat3fl/fl vs. 0.52% ± 0.09% in Stat3∆/∆ tumors, numbers indicate means ± SEM, n = 14). As NK cells produce IFN-γ and TNF-α we reasoned that the decline of NK cell numbers in Stat3∆/∆ tumors accounts for the reduced levels of these cytokines (see Figure 4).
NK cells kill tumor cells without prior sensitization, which allows testing their cytotoxic ability in vitro. Indeed, STAT3-deficient tumor cells were killed less efficiently than their wild-type controls (Figure 5B).
These findings indicate that STAT3 expression in lymphoma cells is required to recruit NK cells as well as to evoke their cytotoxic capacity. NK cell cytotoxicity is regulated by a tight balance of inhibitory and activating signals transmitted from a plethora of different NK cell surface receptors [54,55,56]. When determining the levels of activating NKG2D—(MULT-1 and RAE-1) and NKp46-ligands as well as of inhibitory MHC class I (H-2Kb and H-2Db) on the lymphoma cells we failed to detect any differences in either of these ligands (data not shown). At present we lack definitive knowledge on the underlying mechanism that accounts for impaired NK cell cytotoxicity. We hypothesize that the reduced CCL5 levels in Stat3∆/∆ tumors contribute to this phenomenon as previous studies have described CCL5 as a NK cell activating chemokine . Taken together, these data indicate that the enhanced lymphoma development after STAT3-deletion is associated with reduced NK cell infiltration and cytotoxicity.
2.6. Lymphoma Development in Immune-Compromised Recipients
As our findings show that Stat3∆/∆ tumors recruit and activate NK effector cells less efficiently, we tested lymphoma formation in mice lacking specific lymphocyte subsets.
We first transplanted Stat3fl/fl and Stat3∆/∆ BCR/ABLp185+ tumor cells subcutaneously into Nu/Nu mice lacking T cells, but retaining functional B and NK cells for tumor immune surveillance. Comparable to the outcome of our studies in immune-competent wild-type mice (Figure 3A), transplantation of STAT3-deficient cells into Nu/Nu mice led to significantly enhanced tumor growth (Figure 6A). In contrast, upon transplantation into Rag2−/−γc−/− mice that lack B, T and NK cells, the difference in tumor size was abrogated (Figure 6B). Comparable results were obtained upon transplantation of v-ABLp160+ cells expressing a hairpin targeting STAT3 (STAT3 KD) or a control hairpin (Ctr KD): No difference in tumor size could be detected after transplantation in Rag2−/−γc−/− mice (Figure 6C). It is important to mention that the presence of NK cells is not the only difference in Nu/Nu and Rag2−/−γc−/− mice. In contrast to Rag2−/−γc−/− mice, Nu/Nu mice still harbor B cells. Additionally, Rag2−/−γc−/− may differ in their tumor microenvironment due to the lack of cytokine signaling pathways that rely on the presence of the common γ chain such as IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 . We cannot rule out that the altered cytokine milieu in Rag2−/−γc−/− contribute to the observed effects. Nevertheless we and others have previously shown that NK cells dominate BCR/ABL+ tumor surveillance [27,28,29,58,59]. We thus conclude that STAT3 acts as a tumor suppressor in subcutaneously transplanted BCR/ABL+ lymphoma in the presence of functional NK cells.
This led us to the following concept: in BCR/ABL+ lymphoma STAT3 mediates the recruitment and activation of NK cells. Upon loss of STAT3, NK cells eradicate tumor cells less efficiently resulting in enhanced tumor growth. In BCR/ABL+ lymphoma STAT3 functions as a tumor suppressor as it was shown for brain and intestinal tumors [23,24]. In contrast, in other tumor types STAT3 was described to support tumor growth via the down-regulation of pro-inflammatory cytokines. Moreover, blockade of STAT3 enhanced leukocyte infiltration into the tumor and activated innate immune cells such as macrophages and neutrophils resulting in an increased anti-tumor cytotoxicity [60,61]. Taken together, the entity of studies on STAT3 indicates the following picture: STAT3 cannot be generally judged as a tumor suppressor or tumor promoter—the part STAT3 plays depends on the tumor type and the responsible immune effector cell(s). In BCR/ABL+ lymphoma, which are under the control of NK cells, STAT3 acts as a tumor suppressor.
Mx1-Cre , Stat3fl/fl , Nu/Nu (The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, USA), Rag2−/−γc−/−  and C57BL/6J wild-type mice were maintained under pathogen-free conditions at the Medical University of Vienna and the University of Veterinary Medicine Vienna. All animal experiments were approved by the institutional ethics committee and conform to Austrian laws (license BMWF-68.205/0218-II/3b/2012).
3.2. Generation of BCR/ABL+ Cell Lines, in Vitro Deletion of Endogenous Stat3 and shRNA-Mediated Knockdown
To generate BCR/ABL+ cell lines, BM cells of the offspring of a Stat3fl/fl × Stat3fl/fl Mx1-Cre breeding were transformed retrovirally (by BCR/ABLp185 or v-ABLp160) and maintained in RPMI-1640 supplemented with 10% FCS, 50 µM β-mercaptoethanol and 100 U/mL penicillin, 100 µg/mL streptomycin (PAA) as previously described . For Stat3 deletion, stable Stat3fl/fl Mx1-Cre BCR/ABLp185+ cell lines were incubated for 48 h in 1,000 U/mL recombinant murine interferon-β (IFN-β; PBL Interferon Source, Piscataway, NJ, USA). After two weeks, deletion efficiency was verified by genotyping PCR as described before .
For shRNA-mediated knockdown, hairpins targeting Stat3 were lentivirally transduced into wild-type BCR/ABLp185+ and v-ABLp160+ cells. The encoded hairpin (expressed in a pLKO.1-puro-vector) anneals with the mRNA region transcribed by exon 11 thereby degrading both splice variants of STAT3 (Stat3α and Stat3β). The TRC clone (TRCN0000071456) was obtained from MISSION® shRNA. A clone containing a validated non-silencing shRNA served as control. Selection of vector-expressing cells was accomplished by puromycin selection (1 µg/mL) for 7 days. Efficiency of shRNA-mediated STAT3 knockdown was verified by western blotting.
3.3. Protein Extracts and Western Blotting
Whole cell extracts were performed as previously described [64,65]. For western blotting, proteins (50–100 µg) were separated on a 7% SDS polyacrylamide gel and transferred to nitrocellulose membranes. Membranes were probed with antibodies directed against STAT1 (sc-592, clone M-22), STAT3 (CS#9132), STAT5 (sc-853, clone C-17) and β-actin (A5441, clone AC-15). Immunoreactive bands were visualized by chemiluminescence (20 × LumiGLO® Reagent and 20 × Peroxide, Cell Signaling, , 3 Trask Lane, Danvers, MA, USA).
3.4. Transplantation of Tumor Cells
105 BCR/ABL+ cells were injected subcutaneously into the flanks of wild-type, Nu/Nu and Rag2−/−γc−/− mice. After 11 days or when tumors reached a maximum size of 3 cm3, mice were sacrificed and tumors excised. For flow cytometric analysis tumors were mashed through a 70 µM filter.
Paraffin-embedded tumor samples were stained with CD31 (Dianova (Warburgstr. 45, Hamburg, Germany), DIA-310, dilution 1:40, 90 min) and Ki67 (Novocastra (Hernalser Hauptstrasse 219, Vienna, Austria), MM1, dilution 1:200, 30 min) according to the manufacturers’ instructions.
3.6. Flow Cytometry
Single-cell suspensions were pre-incubated with anti-CD16/CD32 antibodies to prevent non-specific Fc-receptor-mediated binding and then stained with fluorescently labeled antibodies. The following antibodies, all purchased from BD Biosciences, were used: anti-CD3ε (145-2C11), anti-CD49b (DX5), anti-CD4 (L3T4), anti-CD8a (53-6.7), anti-GR1 (RB6-8C5), anti-CD11b (M1/70), anti-B220 (RA3-6B2) and anti-CD19 (1D3).
For cell cycle analysis 106 cells were stained with propidium iodide (50 µg/mL) in a hypotonic lysis solution (0.1% sodium citrate, 0.1% triton X-100, 100 µg/mL RNAse) and incubated at 37 °C for 30 min. Analysis of stained cells was performed using a FACS Canto II flow cytometer equipped with 488, 633 and 405 nm lasers using the FACS Diva software version 6.1.2 (Becton, Dickinson and Company, 1 Becton Drive, Franklin Lakes, NJ, USA).
3.7. [3H]-Thymidine Incorporation
5 × 104 cells were plated in 96-round-bottom-well plates (in triplicates) in the presence of [3H]-thymidine (0.1 μCi/well [0.0037 MBq/well]). After 12 h of incubation, cells were lysed and transferred onto glass fiber filters. Rotiszint® eco plus (ROTH) was added and radioactivity was analyzed in a liquid scintillation counter (Tri-Carb 1900 CA, PerkinElmer, 940 Winter Street, Waltham, MA, USA).
3.8. Real-Time PCR Analysis
RNA was isolated using peqGOLD TriFast reagent. First-strand cDNA synthesis was performed using the iSCRIPT cDNA synthesis kit (Bio-Rad Laboratories, 1000 Alfred Nobel Drive, Hercules, CA, USA) according to the manufacturer’s instructions. Real-time PCR was performed on a MyiQTM2 Cycler (BioRad Laboratories) using SsoFastTM EvaGreen®Supermix (BioRad Laboratories). The following primers were used (Microsynth Austria, Leberstrasse 20, Vienna, Austria): Rplp0_F: 5'-TTCATTGTGGGAGCAGAC-3' and Rplp0_R: 5'-CAGCAGTTTCTCCAGAGC-3'; Il6_F: 5'-TTCCATCCAGTTGCCTTCTTGG-3' and Il6_R: 5'-TTCTCATTTCCACGATTTCCCAG-3'; Il10_F: 5'-AGGGTTACTTGGGTTGCCAA-3' and Il10_R: 5'-CACAGGGGAGAAATCGATGA-3'; Ifng_F: 5'-AAGTGGCATAGATGTGGAAG-3' and Ifng_R: 5'-GAATGCATCCTTTTTCGCCT-3'; Tnfa_F: 5'-GCGGAGTCCGGGCAGGTCTA-3' and Tnfa_R: 5'-GGGGGCTGGCTCTGTGAGGA-3'; Il17_F: 5'-CTGCTGAGCCTGGCGGCTAC-3' and Il17_R: 5'-CATTGCGGTGGAGAGTCCAGGG-3'; Ccl5_F: 5'-CCACTTCTTCTCTGGGTTGG-3' and Ccl5_R: 5'-GTGCCCACGTCAAGGAGTAT-3'. Target gene expression was normalized to the house-keeping gene Rplp0.
3.9. In Vitro NK Cell Cytotoxicity Assay
NK cells were isolated from splenocytes via magnetic-activated cell sorting (MACS; anti-DX5 microbeads, Miltenyi Biotec, Friedrich-Ebert-Straße 68, Bergisch Gladbach, Germany) and cultivated for 7 days in RPMI-1640 containing l-glutamine, 10% FCS, 50 µM β-mercaptoethanol, 100 U/mL penicillin, 100 µg/mL streptomycin and 5,000 U/mL recombinant human IL-2 (Proleukin, Novartis International AG, Basel, Switzerland). NK cells were co-cultured with 5 × 104 CFSE-labeled (2.5 mM; CellTrace CFSE Cell Proliferation Kit, Molecular Probes, 3175 Staley Road, Grand Island, NY, USA) target cells at different effector-to-target (E:T) ratios (10:1, 5:1 and 2.5:1) in triplicates. After 24 h, samples were stained with 7-aminoactinomycin D (7-AAD; 0.1 mg; eBioscience, 10255 Science Center Drive, San Diego, CA, USA) for 5 min and analyzed by flow cytometry: % specific lysis = [% 7-AAD+CFSE+ cells after co-incubation with NK cells] − [% 7-AAD+CFSE+ cells without addition of NK cells] according to .
Therapeutic agents blocking STAT3 are currently under development and predicted to block tumor progression in a variety of malignancies. We show here that in BCR/ABL+ tumors the absence of STAT3 accelerates tumor growth assigning a tumor suppressing function to STAT3 in this disease. We found that STAT3 is required to attract NK cells to the tumor, which restrict and limit tumor growth. In the absence of STAT3 tumor surveillance is significantly impaired. Caution should be taken when targeting STAT3 in lymphoma as it may provoke adverse effects on immune surveillance in these patients.
The authors thank Ofer Mandelboim, Mathias Müller, Thomas Decker, Valeria Poli, Richard Moriggl and Robert Eferl for valuable scientific input. We are indebted to Sabine Fajmann and Katalin Nagy-Bojarszky for excellent technical assistance. This work was supported by the Austrian Science Foundation (FWF P-24295-B23 to A.H.K.; FWF-SFB 28 to V.S.) and the Herzfelder’sche Familienstiftung (to V.S. and A.H.K.).
E.M.P., M.A.H., J.B., Z.B.-H., C.S., B.R. and D.K. performed experiments and analyzed the data. Data interpretation was conducted by E.M.P., M.A.H., J.B., Z.B.-H., C.S., V.S. and A.H.-K. V.S. and F.A. gave conceptual advice and technical support, respectively. V.S. and A.H.-K. designed the study. E.M.P. and A.H.-K. wrote the manuscript.
Conflicts of Interest
The authors declare no conflict of interest.
- Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70, doi:10.1016/S0092-8674(00)81683-9.
- Weinstein, I.B. Cancer. Addiction to oncogenes—The Achilles heal of cancer. Science 2002, 297, 63–64, doi:10.1126/science.1073096.
- Luo, J.; Solimini, N.L.; Elledge, S.J. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 2009, 136, 823–837, doi:10.1016/j.cell.2009.02.024.
- Bowman, T.; Garcia, R.; Turkson, J.; Jove, R. STATs in oncogenesis. Oncogene 2000, 19, 2474–2488, doi:10.1038/sj.onc.1203527.
- Yu, H.; Jove, R. The STATs of cancer—New molecular targets come of age. Nat. Rev. Cancer 2004, 4, 97–105, doi:10.1038/nrc1275.
- Ling, X.; Arlinghaus, R.B. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res. 2005, 65, 2532–2536, doi:10.1158/0008-5472.CAN-04-2425.
- Bar-Natan, M.; Nelson, E.A.; Xiang, M.; Frank, D.A. STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAK-STAT 2012, 1, 55–64, doi:10.4161/jkst.20006.
- Hoelbl, A.; Schuster, C.; Kovacic, B.; Zhu, B.; Wickre, M.; Hoelzl, M.A.; Fajmann, S.; Grebien, F.; Warsch, W.; Stengl, G.; et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol. Med. 2010, 2, 98–110, doi:10.1002/emmm.201000062.
- Bromberg, J. Stat proteins and oncogenesis. J. Clin. Investig. 2002, 109, 1139–1142.
- Buettner, R.; Mora, L.B.; Jove, R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 2002, 8, 945–954.
- Azare, J.; Leslie, K.; Al-Ahmadie, H.; Gerald, W.; Weinreb, P.H.; Violette, S.M.; Bromberg, J. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol. Cell Biol. 2007, 27, 4444–4453, doi:10.1128/MCB.02404-06.
- Abdulghani, J.; Gu, L.; Dagvadorj, A.; Lutz, J.; Leiby, B.; Bonuccelli, G.; Lisanti, M.P.; Zellweger, T.; Alanen, K.; Mirtti, T.; et al. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 2008, 172, 1717–1728, doi:10.2353/ajpath.2008.071054.
- Barbieri, I.; Pensa, S.; Pannellini, T.; Quaglino, E.; Maritano, D.; Demaria, M.; Voster, A.; Turkson, J.; Cavallo, F.; Watson, C.J.; et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res. 2010, 70, 2558–2567, doi:10.1158/0008-5472.CAN-09-2840.
- Gough, D.J.; Corlett, A.; Schlessinger, K.; Wegrzyn, J.; Larner, A.C.; Levy, D.E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324, 1713–1716, doi:10.1126/science.1171721.
- Zhang, Q.; Raje, V.; Yakovlev, V.A.; Yacoub, A.; Szczepanek, K.; Meier, J.; Derecka, M.; Chen, Q.; Hu, Y.; Sisler, J.; et al. Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. J. Biol. Chem. 2013, 288, 31280–31288, doi:10.1074/jbc.M113.505057.
- Kim, D.J.; Angel, J.M.; Sano, S.; DiGiovanni, J. Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis. Oncogene 2009, 28, 950–960, doi:10.1038/onc.2008.453.
- Weber-Nordt, R.M.; Egen, C.; Wehinger, J.; Ludwig, W.; Gouilleux-Gruart, V.; Mertelsmann, R.; Finke, J. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996, 88, 809–816.
- Lin, T.S.; Mahajan, S.; Frank, D.A. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000, 19, 2496–2504, doi:10.1038/sj.onc.1203486.
- Benekli, M.; Baer, M.R.; Baumann, H.; Wetzler, M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 101, 2940–2954, doi:10.1182/blood-2002-04-1204.
- Benekli, M.; Baumann, H.; Wetzler, M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J. Clin. Oncol. 2009, 27, 4422–4432, doi:10.1200/JCO.2008.21.3264.
- Ecker, A.; Simma, O.; Hoelbl, A.; Kenner, L.; Beug, H.; Moriggl, R.; Sexl, V. The dark and the bright side of Stat3: Proto-oncogene and tumor-suppressor. Front. Biosci. 2009, 14, 2944–2958.
- Lee, J.; Kim, J.C.K.; Lee, S.-E.; Quinley, C.; Kim, H.; Herdman, S.; Corr, M.; Raz, E. Signal transducer and activator of transcription 3 (STAT3) protein suppresses adenoma-to-carcinoma transition in Apcmin/+ mice via regulation of Snail-1 (SNAI) protein stability. J. Biol. Chem. 2012, 287, 18182–18189.
- De la Iglesia, N.; Konopka, G.; Puram, S.V.; Chan, J.A.; Bachoo, R.M.; You, M.J.; Levy, D.E.; Depinho, R.A.; Bonni, A. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev. 2008, 22, 449–462, doi:10.1101/gad.1606508.
- Musteanu, M.; Blaas, L.; Mair, M.; Schlederer, M.; Bilban, M.; Tauber, S.; Esterbauer, H.; Mueller, M.; Casanova, E.; Kenner, L.; et al. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 2010, 138, 1003–1011.e5, doi:10.1053/j.gastro.2009.11.049.
- Mair, M.; Zollner, G.; Schneller, D.; Musteanu, M.; Fickert, P.; Gumhold, J.; Schuster, C.; Fuchsbichler, A.; Bilban, M.; Tauber, S.; et al. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology 2010, 138, 2499–2508, doi:10.1053/j.gastro.2010.02.049.
- Vesely, M.D.; Kershaw, M.H.; Schreiber, R.D.; Smyth, M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29, 235–271, doi:10.1146/annurev-immunol-031210-101324.
- Stoiber, D.; Kovacic, B.; Schuster, C.; Schellack, C.; Karaghiosoff, M.; Kreibich, R.; Weisz, E.; Artwohl, M.; Kleine, O.C.; Müller, M.; et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J. Clin. Investig. 2004, 114, 1650–1658.
- Kovacic, B.; Stoiber, D.; Moriggl, R.; Weisz, E.; Ott, R.G.; Kreibich, R.; Levy, D.E.; Beug, H.; Freissmuth, M.; Sexl, V. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006, 10, 77–87.
- Baron, F.; Turhan, A.G.; Giron-Michel, J.; Azzarone, B.; Bentires-Alj, M.; Bours, V.; Bourhis, J.H.; Chouaib, S.; Caignard, A. Leukemic target susceptibility to natural killer cytotoxicity: Relationship with BCR-ABL expression. Blood 2002, 99, 2107–2113, doi:10.1182/blood.V99.6.2107.
- Maghazachi, A.A. Role of chemokines in the biology of natural killer cells. Curr. Top. Microbiol. Immunol. 2010, 341, 37–58.
- Kärre, K.; Ljunggren, H.G.; Piontek, G.; Kiessling, R.; Karre, K. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319, 675–678, doi:10.1038/319675a0.
- Raulet, D.H.; Guerra, N. Oncogenic stress sensed by the immune system: Role of natural killer cell receptors. Nat. Rev. Immunol. 2009, 9, 568–580, doi:10.1038/nri2604.
- Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 2009, 9, 798–809, doi:10.1038/nrc2734.
- Lee, H.; Pal, S.K.; Reckamp, K.; Figlin, R.A.; Yu, H. STAT3: A target to enhance antitumor immune response. Curr. Top. Microbiol. Immunol. 2011, 344, 41–59.
- Niu, G.; Wright, K.L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21, 2000–2008, doi:10.1038/sj.onc.1205260.
- Kortylewski, M.; Yu, H. Role of Stat3 in suppressing anti-tumor immunity. Curr. Opin. Immunol. 2008, 20, 228–233, doi:10.1016/j.coi.2008.03.010.
- Kortylewski, M.; Kujawski, M.; Wang, T.; Wei, S.; Zhang, S.; Pilon-Thomas, S.; Niu, G.; Kay, H.; Mule, J.; Kerr, W.G.; et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11, 1314–1321, doi:10.1038/nm1325.
- Alonzi, T.; Maritano, D.; Gorgoni, B.; Rizzuto, G.; Libert, C.; Poli, V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol. Cell Biol. 2001, 21, 1621–1632, doi:10.1128/MCB.21.5.1621-1632.2001.
- Levy, D.E.; Lee, C. What does Stat3 do? J. Clin. Investig. 2002, 109, 1143–1148.
- Fagard, R.; Metelev, V.; Souissi, I.; Baran-Marszak, F. STAT3 inhibitors for cancer therapy: Have all roads been explored? JAK-STAT 2013, 2, e22882, doi:10.4161/jkst.22882.
- Ilaria, R.L., Jr.; van Etten, R.A. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 1996, 271, 31704–31710, doi:10.1074/jbc.271.49.31704.
- Shuai, K.; Halpern, J.; ten Hoeve, J.; Rao, X.; Sawyers, C.L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996, 13, 247–254.
- Steelman, L.S.; Pohnert, S.C.; Shelton, J.G.; Franklin, R.A.; Bertrand, F.E.; McCubrey, J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18, 189–218, doi:10.1038/sj.leu.2403241.
- Spiekermann, K.; Pau, M.; Schwab, R.; Schmieja, K.; Franzrahe, S.; Hiddemann, W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp. Hematol. 2002, 30, 262–271, doi:10.1016/S0301-472X(01)00787-1.
- Aggarwal, B.B.; Kunnumakkara, A.B.; Harikumar, K.B.; Gupta, S.R.; Tharakan, S.T.; Koca, C.; Dey, S.; Sung, B. Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship? Ann. NY Acad. Sci. 2009, 1171, 59–76, doi:10.1111/j.1749-6632.2009.04911.x.
- Bromberg, J.F.; Wrzeszczynska, M.H.; Devgan, G.; Zhao, Y.; Pestell, R.G.; Albanese, C.; Darnell, J.E. Stat3 as an oncogene. Cell 1999, 98, 295–303, doi:10.1016/S0092-8674(00)81959-5.
- Levy, D.E.; Inghirami, G. STAT3: A multifaceted oncogene. Proc. Natl. Acad. Sci. USA 2006, 103, 10151–10152, doi:10.1073/pnas.0604042103.
- Ishida, Y.; Kondo, T.; Takayasu, T.; Iwakura, Y.; Mukaida, N. The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J. Immunol. 2004, 172, 1848–1855.
- Shinozaki, M.; Okada, Y.; Kitano, A.; Ikeda, K.; Saika, S.; Shinozaki, M. Impaired cutaneous wound healing with excess granulation tissue formation in TNFalpha-null mice. Arch. Dermatol. Res. 2009, 301, 531–537, doi:10.1007/s00403-009-0969-z.
- Schall, T.J.; Bacon, K.; Toy, K.J.; Goeddel, D.V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990, 347, 669–671, doi:10.1038/347669a0.
- Allavena, P.; Germano, G.; Marchesi, F.; Mantovani, A. Chemokines in cancer related inflammation. Exp. Cell Res. 2011, 317, 664–673, doi:10.1016/j.yexcr.2010.11.013.
- Taub, D.D.; Sayers, T.J.; Carter, C.R.; Ortaldo, J.R. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J. Immunol. 1995, 155, 3877–3888.
- Ming, W.J.; Bersani, L.; Mantovani, A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J. Immunol. 1987, 138, 1469–1474.
- Vivier, E.; Raulet, D.H.; Moretta, A.; Caligiuri, M.A.; Zitvogel, L.; Lanier, L.L.; Yokoyama, W.M.; Ugolini, S. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331, 44–49, doi:10.1126/science.1198687.
- Orr, M.T.; Lanier, L.L. Natural killer cell education and tolerance. Cell 2010, 142, 847–856, doi:10.1016/j.cell.2010.08.031.
- Koch, J.; Steinle, A.; Watzl, C.; Mandelboim, O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013, 34, 182–191.
- Kovanen, P.E.; Leonard, W.J. Cytokines and immunodeficiency diseases: Critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 2004, 202, 67–83, doi:10.1111/j.0105-2896.2004.00203.x.
- Putz, E.M.; Gotthardt, D.; Hoermann, G.; Csiszar, A.; Wirth, S.; Berger, A.; Straka, E.; Rigler, D.; Wallner, B.; Jamieson, A.M.; et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep. 2013, 4, 437–444, doi:10.1016/j.celrep.2013.07.012.
- Zebedin, E.; Simma, O.; Schuster, C.; Putz, E.M.; Fajmann, S.; Warsch, W.; Eckelhart, E.; Stoiber, D.; Weisz, E.; Schmid, J.A.; et al. Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood 2008, 112, 4655–4664, doi:10.1182/blood-2008-02-139105.
- Yu, H.; Kortylewski, M.; Pardoll, D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7, 41–51, doi:10.1038/nri1995.
- Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S.; Bhattacharya, R.; Gabrilovich, D.; Heller, R.; Coppola, D.; et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10, 48–54.
- Kühn, R.; Schwenk, F.; Aguet, M.; Rajewsky, K. Inducible gene targeting in mice. Science 1995, 269, 1427–1429, doi:10.1126/science.7660125.
- Cao, X.; Shores, E.W.; Hu-Li, J.; Anver, M.R.; Kelsall, B.L.; Russell, S.M.; Drago, J.; Noguchi, M.; Grinberg, A.; Bloom, E.T.; et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 1995, 2, 223–238, doi:10.1016/1074-7613(95)90047-0.
- Schreiber, E.; Matthias, P.; Müller, M.M.; Schaffner, W. Rapid detection of octamer binding proteins with “mini-extracts”, prepared from a small number of cells. Nucleic Acids Res. 1989, 17, 6419, doi:10.1093/nar/17.15.6419.
- Hoelbl, A.; Kovacic, B.; Kerenyi, M.A.; Simma, O.; Warsch, W.; Cui, Y.; Beug, H.; Hennighausen, L.; Moriggl, R.; Sexl, V. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 2006, 107, 4898–4906, doi:10.1182/blood-2005-09-3596.
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).